Compare Autozone Inc (AZO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Sana Biotechnology Inc — how do they compare? Autozone Inc trades at $3,042 (market cap $49.67B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Autozone Inc is far larger — about 44× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | SANA | |
|---|---|---|
Market Cap | $49.67B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $5.92 |
52-Week Low | $2.92K | $2.68 |
Enterprise Value | $62.05B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,045.87, down 0.72% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though recent Q3 2025 EPS missed expectations while Q4 2025 and Q1 2026 beat. Operating cash flow remains robust at $3.12B, supporting ongoing expansion initiatives. Recent organizational changes and international growth strategies highlight management's focus on long-term value creation.
AZO presents a compelling value opportunity with 72.7% analyst buy ratings and $3,730 consensus price target representing 22% upside. Key risks include margin compression trends and competitive pressures in auto parts retail. The stock's current technical weakness contrasts with strong institutional conviction, creating potential for recovery if earnings momentum improves.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
